(4-苄基氧基羰基氨基苯基)-乙酸 | 17859-70-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-苄基氧基羰基氨基苯基)-乙酸
• 英文名称: p-(Benzyloxycarbonylamino)-phenylessigsaeure
• 英文别名: (4-Benzyloxycarbonylaminophenyl)-acetic acid；2-[4-(phenylmethoxycarbonylamino)phenyl]acetic acid
• CAS: 17859-70-0
• 化学式: C₁₆H₁₅NO₄
• mdl: MFCD05662731
• 分子量: 285.299
• InChiKey: GIXZPLVJWDISOJ-UHFFFAOYSA-N

物化性质

• 熔点：
  156.5-157.0 °C(Solv: methanol (67-56-1); water (7732-18-5))
• 沸点：
  441.6±38.0 °C(Predicted)
• 密度：
  1.314±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  (4-苄基氧基羰基氨基苯基)-乙酸 在 碳酸氢钠 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.0h， 生成 1-N-[4-(benzyloxycarbonylamino)phenylethanoyl]-6-O-[2-N-[4-(benzyloxycarbonyl)butylamino]ethylamino]-3,2',6'-tris(N-benzyloxycarbonyl)neamine
  参考文献：
  名称：

  Design of Novel Antibiotics that Bind to the Ribosomal Acyltransfer Site

  摘要：

  The structure of neamine bound to the A site of the bacterial ribosomal RNA was used in the design of novel aminoglycosides. The design took into account stereo and electronic contributions to interactions between RNA and aminoglycosides, as well as a random search of 273 000 compounds from the Cambridge structural database and the National Cancer Institute 3-D database that would fit in the ribosomal aminoglycoside-binding pocket. A total of seven compounds were designed and subsequently synthesized, with the expectation that they would bind to the A-site RNA. Indeed, all synthetic compounds were found to bind to the target RNA comparably to the parent antibiotic neamine, with dissociation constants in the lower micromolar range. The synthetic compounds were evaluated for antibacterial activity against a set of important pathogenic bacteria. These designer antibiotics showed considerably enhanced antibacterial activities against these pathogens, including organisms that hyperexpressed resistance enzymes to aminoglycosides. Furthermore, analyses of four of the synthetic compounds with two important purified resistance enzymes for aminoglycosides indicated that the compounds were very poor substrates; hence the activity of these synthetic antibiotics does not appear to be compromised by the existing resistance mechanisms, as supported by both in vivo and in vitro experiments. The design principles disclosed herein hold the promise of the generation of a large series of designer antibiotics uncompromised by the existing mechanisms of resistance.

  DOI：

  10.1021/ja011695m
• 作为产物：
  描述：

  对氨基乙酸苯甲酯 在 水 、 三乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 (4-苄基氧基羰基氨基苯基)-乙酸
  参考文献：
  名称：

  Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonists

  摘要：

  A novel class of human beta(3)-adrenergic receptor agonists was designed in effort to improve selectivity and metabolic stability versus previous disclosed beta(3)-AR agonists. As observed, many of the beta(3)-AR agonists seem to need the acyclic ethanolamine core for agonist activity. We have synthesized derivatives that constrained this moiety by introduction of a pyrrolidine. This unique modification maintains human beta(3) functional potency with improved selectivity versus ancillary targets and also eliminates the possibility of the same oxidative metabolites formed from cleavage of the N-C bond of the ethanolamine. Compound 39 exhibited excellent functional beta(3) agonist potency across species with good pharmacokinetic properties in rat, dog, and rhesus monkeys. Early de-risking of this novel pyrrolidine core (44) via full AMES study supports further research into various new beta(3)-AR agonists containing the pyrrolidine moiety. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.087

文献信息

• Melanin concentrating hormone antagonist
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07115750B1

  公开（公告）日：2006-10-03

  A melanin-concentrating hormone antagonist which comprises a compound of the formula: wherein Ar1 is a cyclic group which may have substituents; X is a spacer having a main chain of 1 to 6 atoms; Y is a bond or a spacer having a main chain of 1 to 6 atoms; Ar is a monocyclic aromatic ring which may be condensed with a 4 to 8 membered non-aromatic ring, and may have further substituents; R1 and R2 are independently hydrogen atom or a hydrocarbon group which may have substituents; R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; R2 may form a spiro ring together with Ar; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents; or a salt thereof; which is useful as an agent for preventing or treating obesity, etc.

  一种黑色素浓缩激素拮抗剂，包括以下式的化合物： 其中Ar1是可能具有取代基团的环状基团； X是具有1到6个原子的主链的间隔物； Y是键或具有1到6个原子的主链的间隔物； Ar是可能与4到8个成员的非芳香环融合的单环芳香环，并且可能具有进一步的取代基团； R1和R2分别是氢原子或可能具有取代基团的碳氢基团；R1和R2，连同相邻的氮原子，可能形成可能具有取代基团的含氮杂环；R2可能与Ar一起形成螺环；或者R2，连同相邻的氮原子和Y，可能形成可能具有取代基团的含氮杂环；或其盐； 该化合物可用作预防或治疗肥胖等疾病的药剂。
• Selective, Tight-Binding Inhibitors of Integrin α4β1 That Inhibit Allergic Airway Responses
  作者：Ko-chung Lin、Humayun S. Ateeq、Sherry H. Hsiung、Lillian T. Chong、Craig N. Zimmerman、Alfredo Castro、Wen-cherng Lee、Charles E. Hammond、Sandhya Kalkunte、Ling-Ling Chen、R. Blake Pepinsky、Diane R. Leone、Andrew G. Sprague、William M. Abraham、Alan Gill、Roy R. Lobb、Steven P. Adams

  DOI：10.1021/jm980673g

  日期：1999.3.1

  development of nonspecific airway hyperresponsiveness to carbachol. These results show that highly selective and potent small-molecule antagonists can be identified to integrins with primary specificity for peptide domains other than Arg-Gly-Asp (RGD); they confirm the generality of integrins as small molecule targets; and they validate alpha4beta1 as a therapeutic target for asthma.

  整联蛋白α4beta1介导白细胞募集，激活，介质释放和凋亡抑制，并且它在炎症病理生理学中发挥着核心作用。描述了基于来自细胞纤连蛋白交替剪接的连接段1（CS-1）肽的Leu-Asp-Val（LDV）序列的高亲和力，选择性的alpha4beta1抑制剂，该抑制剂采用了新型N端肽“上限”策略。一种抑制剂BIO-1211的效价比起始肽高约10（6）倍，并表现出紧密结合的特性（koff = 1.4 x 10（-4）s-1，KD = 70 pM），这是一个了不起的发现用于蛋白质受体的非共价小分子抑制剂。BIO-1211对激活形式的alpha4beta1也具有200倍的选择性，并且它刺激整联蛋白beta1亚基上配体诱导的表位的表达，与受体的配体结合位点的占有率一致的性质。用3毫克雾化剂量的BIO-1211预处理过敏羊可抑制抗原攻击后的早期和晚期气道反应，并防止非特异性气道对卡巴胆碱的过度反应。这些结果表
• [EN] CELL ADHESION INHIBITORS<br/>[FR] INHIBITEURS DE L'ADHERENCE CELLULAIRE
  申请人：BIOGEN, INC.

  公开号：WO1996022966A1

  公开（公告）日：1996-08-01

  (EN) The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.(FR) L'invention concerne de nouveaux composés utiles pour inhiber et prévenir l'adhérence cellulaire, ainsi que les pathologies provoquées par l'adhérence cellulaire. Elle concerne également des compositions pharmaceutiques contenant ces composés, ainsi que des procédés permettant de les utiliser pour inhiber et prévenir l'adhérence cellulaire et les pathologies provoquées par l'adhérence cellulaire. On peut utiliser ces composés et ces compositions pharmaceutiques en tant qu'agents thérapeutiques et prophylactiques. Ils sont particulièrement appropriés pour le traitement de nombreuses maladies inflammatoires et auto-immunes.

  本发明涉及新型化合物，可用于抑制和预防细胞黏附和细胞黏附介导的病理过程。本发明还涉及包含这些化合物的制药配方和使用它们抑制和预防细胞黏附和细胞黏附介导的病理过程的方法。本发明的化合物和制药组合物可用作治疗或预防剂。它们特别适用于治疗许多炎症和自身免疫性疾病。
• Cell adhesion inhibitors
  申请人：——

  公开号：US20030018016A1

  公开（公告）日：2003-01-23

  The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.

  本发明涉及新型化合物，其对细胞粘附和细胞粘附介导的病理过程的抑制和预防具有用处。本发明还涉及包含这些化合物的制药配方和使用它们抑制和预防细胞粘附和细胞粘附介导的病理过程的方法。本发明的化合物和制药组合物可用作治疗或预防剂。它们特别适用于治疗许多炎症和自身免疫性疾病。
• Agent for preventing or treating neuropathy
  申请人：Momose Yu

  公开号：US20060004069A1

  公开（公告）日：2006-01-05

  The present invention provides an agent for preventing or treating neuropathy having superior action and low toxicity. This agent comprises a compound represented by the formula: wherein ring A is a 5-membered aromatic heterocycle containing 2 or more nitrogen atoms, which may further have substituent(s); B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a divalent acyclic hydrocarbon group; Z is —O—, —S—, —NR 2 —, —CONR 2 — or —NR 2 CO— (R 2 is a hydrogen atom or an optionally substituted alkyl group); Y is a bond or a divalent acyclic hydrocarbon group; R 1 is an optionally substituted cyclic group, an optionally substituted amino group or an optionally substituted acyl group, provided that when the 5-membered aromatic heterocycle represented by ring A is imidazole, then Z should not be —O—, or a salt thereof.

  本发明提供了一种用于预防或治疗神经病的药剂，具有优异的作用和低毒性。该药剂包括以下式子所表示的化合物：其中环A是一个含有2个或更多氮原子的5元芳香杂环，可以进一步具有取代基；B是一个可选取代的碳氢化合物基团或可选取代的杂环基团；X是一个二价的无环碳氢基团；Z是—O—、—S—、—NR2—、—CONR2—或—NR2CO—（其中R2是氢原子或可选取代的烷基基团）；Y是一个键或一个二价的无环碳氢基团；R1是一个可选取代的环基、可选取代的氨基或可选取代的酰基，但当环A所表示的5元芳香杂环是咪唑时，Z不应为—O—，或其盐。